



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

产品名称: **GSK2190915 (sodium salt)**

产品别名: **Fiboflapon sodium**

生物活性:				
Description	Fiboflapon sodium (GSK2190915 (sodium salt)) is a potent FLAP(5-Lipoxygenase-activating protein) inhibitor with binding IC ₅₀ of 2.9 nM.			
IC₅₀ & Target	IC ₅₀ : 76 nM (inhibition of LTB ₄ in human blood 5 h incubation)[1].			
In Vitro	Fiboflapon (AM803) exhibits excellent preclinical toxicology and pharmacokinetics in rat and dog. Fiboflapon (AM803) also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model[1]. Oral administration of Fiboflapon (AM803) (1 mg/kg) resulted in sustained inhibition of ex vivo ionophore-challenged whole blood LTB ₄ biosynthesis with >90% inhibition for up to 12 h and an EC ₅₀ of approximately 7 nM. When rat lungs were challenged in vivo with calcium-ionophore, Fiboflapon (AM803) inhibited LTB ₄ and cysteinyl leukotriene (CysLT) production with ED ₅₀ s of 0.12 mg/kg and 0.37 mg/kg, respectively. The inhibition measured 16 h following a single oral dose of 3 mg/kg was 86% and 41% for LTB ₄ and CysLTs, respectively. In an acute inflammation setting, Fiboflapon (AM803) dose-dependently reduced LTB ₄ , CysLTs, plasma protein extravasation and neutrophil influx induced by peritoneal zymosan injection. Finally, AM803 increased survival time in mice exposed to a lethal intravenous injection of platelet activating factor (PAF)[2].			
Solvent&Solubility	In Vitro: DMSO : ≥ 32 mg/mL (48.50 mM) * "≥" means soluble, but saturation unknown.			
	Preparing Stock Solutions	Solvent	Mass	
		Concentration		
			1 mg	5 mg
				10 mg
		1 mM	1.5156 mL	7.5779 mL
		5 mM	0.3031 mL	1.5156 mL
		10 mM	0.1516 mL	0.7578 mL
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液, 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month. -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。			
References	[1]. Stock NS, et al. 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor. J Med Chem. 2011 Dec 8;54(23):8013-29. [2]. Lorrain DS, et al. Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. Eur J Pharmacol. 2010 Aug 25;640(1-3):211-8.			